NAMS

NewAmsterdam Pharma Co N.V. NAMS

NasdaqMid CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,912 of 2,925

Why it scores 7Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$3.70M

Quarter to Jun 30

Net income

$-64.14M

Quarter to Jun 30

Free cash flow

$-39.29M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$4.16B total
Frazier Life Sciences Management, L.P.
$623.73M+6.6%
Capital World Investors
$414.49M+10.1%
FMR LLC
$350.41M+18.0%
RA CAPITAL MANAGEMENT, L.P.
$330.78M0.0%
FCPM III SERVICES B.V.
$287.74M-7.7%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$146.52M0.0%
VIKING GLOBAL INVESTORS LP
$142.46M0.0%
Bain Capital Life Sciences Investors, LLC
$131.14M-47.3%
MAVERICK CAPITAL LTD
$110.75M+49.5%
Duquesne Family Office LLC
$104.05M0.0%
Jupiter Topco LLC
$86.01M--
Medicxi Ventures Management (Jersey) Ltd
$74.85M-17.4%
JENNISON ASSOCIATES LLC
$71.25M-23.6%
Orbis Allan Gray Ltd
$59.23MNew
Polar Capital Holdings Plc
$58.44M-39.1%
Capital International Investors
$58.41M+19.6%
GOLDMAN SACHS GROUP INC
$52.36M-20.6%
WESTFIELD CAPITAL MANAGEMENT CO LP
$52.07M-30.3%
Castle Hook Partners LP
$46.46M+31.5%
AMERIPRISE FINANCIAL INC
$42.48M+66.5%
ALLIANCEBERNSTEIN L.P.
$40.33M+5.1%
PRICE T ROWE ASSOCIATES INC /MD/
$39.56MNew
JPMORGAN CHASE & CO
$38.37M+28.1%
abrdn plc
$37.37M+31.8%
BlackRock, Inc.
$36.05M+20.0%
See all 198 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/NAMS

Earnings Per Share

13fpro.ai/company/NAMS

Loading ratio trend…

NAMS key financials by period

Reported revenue, net income and operating margin by fiscal year, from NewAmsterdam Pharma Co N.V.'s annual filings on SEC EDGAR.

NewAmsterdam Pharma Co N.V. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$22.5M$-203.8M—
FY 2024$45.6M$-241.6M—
FY 2023$14.1M$-176.9M—
FY 2022$102.7M$-22.6M-3.5%
Source: NAMS filings on SEC EDGAR →

Companies similar to NAMS

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

NAMS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About NewAmsterdam Pharma Co N.V. (NAMS): stock profile, AI score and financials

NewAmsterdam Pharma Co N.V. (NAMS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NAMS at 6.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,912 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), NewAmsterdam Pharma Co N.V. reports quarterly revenue of $3.7M, net income of $-64.1M, free cash flow of $-39.3M. Top institutional holders of NAMS by reported 13-F value include Frazier Life Sciences Management, L.P., Capital World Investors, FMR, based on the most recent SEC filings. NAMS trades on the Nasdaq exchange and files with the SEC under CIK 1936258. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NAMS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NewAmsterdam Pharma Co N.V. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1936258 →